Assenagon Asset Management S.A. Has $527,000 Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Assenagon Asset Management S.A. increased its stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 36.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 353,837 shares of the company’s stock after buying an additional 93,809 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.69% of PMV Pharmaceuticals worth $527,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in PMV Pharmaceuticals by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,452,111 shares of the company’s stock valued at $4,169,000 after acquiring an additional 46,804 shares during the last quarter. Acadian Asset Management LLC lifted its stake in PMV Pharmaceuticals by 170.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,080,194 shares of the company’s stock valued at $3,533,000 after purchasing an additional 1,311,745 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in PMV Pharmaceuticals by 92.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 826,704 shares of the company’s stock worth $1,405,000 after purchasing an additional 397,062 shares during the period. Opaleye Management Inc. acquired a new position in PMV Pharmaceuticals during the first quarter worth approximately $802,000. Finally, Cubist Systematic Strategies LLC increased its position in PMV Pharmaceuticals by 570.8% during the second quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company’s stock worth $113,000 after buying an additional 59,452 shares during the last quarter. 90.20% of the stock is owned by institutional investors.

PMV Pharmaceuticals Stock Performance

Shares of PMVP opened at $1.63 on Monday. The firm has a market cap of $83.98 million, a P/E ratio of -1.68 and a beta of 1.49. PMV Pharmaceuticals, Inc. has a 52 week low of $1.40 and a 52 week high of $3.47. The firm’s 50-day simple moving average is $1.54 and its 200 day simple moving average is $1.66.

PMV Pharmaceuticals (NASDAQ:PMVP) last posted its earnings results on Thursday, August 8th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. As a group, equities analysts forecast that PMV Pharmaceuticals, Inc. will post -1.05 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $5.75.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.